



Register of declared interests – Topic-specific

SHTG IMTO: Minuteful Kidney for home testing of albumin-to-creatinine ratio (ACR)

| Name | Date of declaration | Project element | Specific Personal Financial (2.1) | Specific Personal non-financial (2.3) | Specific non-personal financial (2.2) | Specific non-personal non-financial (2.4) | Non-specific Personal Financial | Non-specific Personal Non-financial | Non-specific non-personal financial | Non-specific non-personal non-financial |
|-----------------|---------------------|-----------------|-----------------------------------|---------------------------------------|---------------------------------------|---|--|-------------------------------------|-------------------------------------|---|
| Alison Grant | 02/02/22 | Peer Review | None | None | None | None | None | None | None | None |
| Aileen Dunleavy | 26/01/22 | Peer Review | None | None | None | None | Vifor/Fresenius - Advisory board – External advisor | None | None | None |
| Ben Reynolds | 14/01/22 | Peer Review | None | None | None | None | -Alexion Pharmaceuticals Ltd: Previous honoraria for educational events - Maynard Consulting: Honororia for clinician surveys - Dept of Paediatric Nephrology: KRUK Innovation Grant Innovation grant is for the development of a | None | None | None |

| Name | Date of declaration | Project element | Specific Personal Financial | Specific Personal non-financial | Specific non-personal financial | Specific non-personal non-financial | Non-specific Personal Financial | Non-specific Personal Non-financial | Non-specific non-personal financial | Non-specific non-personal non-financial |
|------|---------------------|-----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---|
|------|---------------------|-----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---|

| | | | | | | | | | | |
|---------------|----------|-------------|------|------|------|------|--|---|------|------|
| | | | | | | | virtual reality based teaching tool for dialysis - I am personally named as the main grant holder - Dept of Paediatric Nephrology: KRUK Small Project Grant The small project grant was looking at the long-term outcomes following haemolytic uraemic syndrome, awarded to my research fellow with my name as a co-applicant. | | | |
| Jamie Traynor | 25/01/22 | Peer Review | None | None | None | None | None | None | None | None |
| *Neil Turner | 21/01/22 | Peer Review | None | None | None | None | -Shire-Takeda: Advisory board, speaker - Sanofi-Genzyme: Advisory board, speaker, from 2019 -Purespring: Consultancy, from 2021 | - Alport UK: Trustee, speaker, educator, campaigner - UK Kidney Association: Advising on patient engagement and activation (patientview.org founder) - UK Kidney Association: Member of | None | None |

| Name | Date of declaration | Project element | Specific Personal Financial | Specific Personal non-financial | Specific non-personal financial | Specific non-personal non-financial | Non-specific Personal Financial | Non-specific Personal Non-financial | Non-specific non-personal financial | Non-specific non-personal non-financial |
|------|---------------------|-----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---|
|------|---------------------|-----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---|

| | | | | | | | | | | |
|----------------|----------|-------------|--|-----------------------------------|------|------|------|-------------------------|------|--|
| | | | | | | | | international committee | | |
| Andrea Brown | 18/01/22 | Peer Review | None | None | None | None | None | None | None | None |
| David Stephens | 14/02/22 | Peer Review | <p>Director at Dr David Stephens Ltd</p> <p>Joint Leader Apprasier at NHS Highland - managing the appraisal system for GPs in Highland</p> <p>Specialist Advisor Care Quality Commission (CQC) - visiting usually in person but can be on line GP practices, Out of Hours organisation, Walk in Centers, Private Practice and Digital Providers in England & Isle of Man</p> | | | | | | | <p>Articles and Guidelines on Osteoporosis - Guidelines in Practice (2021)</p> <p>Podcast for Royal College of General Practitioners (RCGP) on Osteoporosis (2021)</p> |
| Kashaf Ali | 28/02/22 | Peer Review | NOVONORDISK , Speaker fees on | Diabetes Scotland , attendee at a | | | | | | |

| Name | Date of declaration | Project element | Specific Personal Financial | Specific Personal non-financial | Specific non-personal financial | Specific non-personal non-financial | Non-specific Personal Financial | Non-specific Personal Non-financial | Non-specific non-personal financial | Non-specific non-personal non-financial |
|------|---------------------|-----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---|
|------|---------------------|-----------------|-----------------------------|---------------------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|-------------------------------------|---|

| | | | | | | | | | | |
|--|--|--|--|---|--|--|--|--|--|--|
| | | | Diabetes and Obesity-related topics , ASTRAZENECA , Speaker fees on Diabetes and Diabetic Kidney Disease , NAPP , Advisory Board and Speaker Fees on Diabetes related topics , BOEHRINGER-INGELHEIM , Speaker fees on Diabetes related topics , | Scottish Advisory Council meeting RCGP Scotland, elected as a executive board member | | | | | | |
|--|--|--|--|---|--|--|--|--|--|--|

***Further details:**

Shire-Takeda and Sanofi-Genzyme involvement is around awareness and treatment of rare diseases, though in both cases their commercial interests centre mainly on one condition, Fabry disease. This is a lysosomal storage disorder that has a very expensive treatment with two competing enzyme replacement products, made by these two companies. I have contributed to several educational meetings on the broad topic of rare diseases sponsored by the two companies, and to advisory boards discussing approaches to the identification of patients with Fabry disease, and on how to raise clinician awareness of this condition specifically, and rare diseases more generally.

Purespring is a recent Bristol-based start-up around gene therapy treatments for genetic diseases affecting the glomerulus. One of their target diseases is Alport Syndrome, a condition that I have studied closely in the laboratory and clinically. It is the second most common inherited cause of dialysis and transplant-requiring kidney disease, responsible for 1-2% of end stage kidney disease.